JP7607951B2 - 妊娠性糖尿病に関する代謝プロファイルスクリーニング - Google Patents

妊娠性糖尿病に関する代謝プロファイルスクリーニング Download PDF

Info

Publication number
JP7607951B2
JP7607951B2 JP2022521574A JP2022521574A JP7607951B2 JP 7607951 B2 JP7607951 B2 JP 7607951B2 JP 2022521574 A JP2022521574 A JP 2022521574A JP 2022521574 A JP2022521574 A JP 2022521574A JP 7607951 B2 JP7607951 B2 JP 7607951B2
Authority
JP
Japan
Prior art keywords
subject
acid
diabetes mellitus
marker
metabolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022521574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551656A (ja
JP2022551656A5 (https=
Inventor
ジェー． クース，ブライアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2022551656A publication Critical patent/JP2022551656A/ja
Publication of JP2022551656A5 publication Critical patent/JP2022551656A5/ja
Application granted granted Critical
Publication of JP7607951B2 publication Critical patent/JP7607951B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2022521574A 2019-10-11 2020-10-09 妊娠性糖尿病に関する代謝プロファイルスクリーニング Active JP7607951B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962914294P 2019-10-11 2019-10-11
US62/914,294 2019-10-11
PCT/US2020/055020 WO2021072222A1 (en) 2019-10-11 2020-10-09 Metabolic profile screening for gestational diabetes

Publications (3)

Publication Number Publication Date
JP2022551656A JP2022551656A (ja) 2022-12-12
JP2022551656A5 JP2022551656A5 (https=) 2023-10-17
JP7607951B2 true JP7607951B2 (ja) 2025-01-06

Family

ID=75436783

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022521574A Active JP7607951B2 (ja) 2019-10-11 2020-10-09 妊娠性糖尿病に関する代謝プロファイルスクリーニング

Country Status (8)

Country Link
US (1) US20240085432A1 (https=)
EP (1) EP4022299A4 (https=)
JP (1) JP7607951B2 (https=)
KR (1) KR20220079582A (https=)
CN (1) CN114761794A (https=)
AU (1) AU2020361608A1 (https=)
CA (1) CA3157057A1 (https=)
WO (1) WO2021072222A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114167066B (zh) * 2022-01-24 2022-06-21 杭州凯莱谱精准医疗检测技术有限公司 生物标志物在制备妊娠糖尿病诊断试剂中的用途
CN117187381B (zh) * 2023-11-03 2024-02-13 南京医科大学 一种用于妊娠期糖尿病早期辅助诊断的甲基化区域标志物组合及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058142A2 (en) 2003-12-16 2005-06-30 Emory University Diabetes diagnostic
JP2019027885A (ja) 2017-07-28 2019-02-21 国立大学法人千葉大学 妊娠糖尿病の発症リスクの診断用バイオマーカー
US20190310269A1 (en) 2018-04-04 2019-10-10 Human Longevity, Inc. Systems and methods for measuring obesity using metabolome analysis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2690541A1 (en) * 2007-07-17 2009-01-29 Metabolon, Inc. Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same
WO2012058298A1 (en) * 2010-10-26 2012-05-03 Mayo Foundation For Medical Education And Research Biomarkers of reduced insulin action
EP3094968B1 (en) * 2014-01-15 2020-12-09 The Regents of The University of California Metabolic screening for gestational diabetes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058142A2 (en) 2003-12-16 2005-06-30 Emory University Diabetes diagnostic
JP2019027885A (ja) 2017-07-28 2019-02-21 国立大学法人千葉大学 妊娠糖尿病の発症リスクの診断用バイオマーカー
US20190310269A1 (en) 2018-04-04 2019-10-10 Human Longevity, Inc. Systems and methods for measuring obesity using metabolome analysis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIU, Tianhu et al.，Comprehensive analysis of serum metabolites in gestational diabetes mellitus by UPLC/Q-TOF-MS，Anal Bioanal Chem，2016年，408(4)，1125-1135
PRIYADARSINI, Shrestha et al.，Complete metabolome and lipidome analysis reveals novel biomarkers in the human diabetic corneal stroma，Exp Eye Res，2016年，153，90-100

Also Published As

Publication number Publication date
AU2020361608A1 (en) 2022-04-21
EP4022299A4 (en) 2023-03-01
JP2022551656A (ja) 2022-12-12
CN114761794A (zh) 2022-07-15
KR20220079582A (ko) 2022-06-13
EP4022299A1 (en) 2022-07-06
WO2021072222A1 (en) 2021-04-15
US20240085432A1 (en) 2024-03-14
CA3157057A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
Nelson et al. Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review
Bramham et al. Diagnostic and predictive biomarkers for pre-eclampsia in patients with established hypertension and chronic kidney disease
Rawal et al. A longitudinal study of thyroid markers across pregnancy and the risk of gestational diabetes
Singer et al. Urinary neutrophil gelatinase-associated lipocalin distinguishes pre-renal from intrinsic renal failure and predicts outcomes
AU2010240781B2 (en) Methods for determining maternal health risks
Ravnsborg et al. First-trimester proteomic profiling identifies novel predictors of gestational diabetes mellitus
Bozkurt et al. Adiponectin and leptin at early pregnancy: association to actual glucose disposal and risk for GDM—a prospective cohort study
Ravnsborg et al. First-trimester multimarker prediction of gestational diabetes mellitus using targeted mass spectrometry
US20210293824A1 (en) Preeclampsia biomarkers and related systems and methods
Lehmann et al. Metabolic profiles during an oral glucose tolerance test in pregnant women with and without gestational diabetes
Herrera et al. Revisiting the placental clock: Early corticotrophin-releasing hormone rise in recurrent preterm birth
Shaarbaf Eidgahi et al. Diagnostic accuracy of first and early second trimester multiple biomarkers for prediction of gestational diabetes mellitus: a multivariate longitudinal approach
Yu et al. Changes of serum pentraxin-3 and hypersensitive CRP levels during pregnancy and their relationship with gestational diabetes mellitus
Delić et al. Optimal laboratory panel for predicting preeclampsia
Oğlak et al. The reduced serum concentrations of β-arrestin-1 and β-arrestin-2 in pregnancies complicated with gestational diabetes mellitus
JP7607951B2 (ja) 妊娠性糖尿病に関する代謝プロファイルスクリーニング
Tamblyn et al. Serum and urine vitamin D metabolite analysis in early preeclampsia
Liu et al. Putrescine as a novel biomarker of maternal serum in first trimester for the prediction of gestational diabetes mellitus: A nested case-control study
Zorba et al. Visfatin serum levels are increased in women with preeclampsia: a case-control study
Erbağcı et al. Association between early oxidative DNA damage and iron status in women with gestational diabetes mellitus
Gul Kara et al. Maternal and cord serum levels of sFlt-1 and PlGF in pregnancies complicated by gestational diabetes mellitus: a prospective cohort study
Huhn et al. The utility of early gestational OGTT and biomarkers for the development of gestational diabetes mellitus: an international prospective multicentre cohort study
Pecks et al. A mass spectrometric multicenter study supports classification of preeclampsia as heterogeneous disorder
Vajrychova et al. Quantification of intra-amniotic inflammation in late preterm prelabour rupture of membranes
Takahashi et al. Early-pregnancy N-terminal pro-brain natriuretic peptide level is inversely associated with hypertensive disorders of pregnancy diagnosed after 35 weeks of gestation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231006

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241211

R150 Certificate of patent or registration of utility model

Ref document number: 7607951

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150